Michel Vounatsos, Biogen CEO (via YouTube)
Biogen spotlights a pair of painful pipeline setbacks as aducanumab showdown looms at the FDA
Biogen has flagged a pair of setbacks in the pipeline, spotlighting the final failure for a one-time top MS prospect while scrapping a gene therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
